I agree. But if tens of thousands of people are dying and someone of authority says something helps, you think people won't take the chance by any means? It was irresponsible at best.
Not his faultDay late and a dollar short.@MMAHAWK already got us all riled up.
He was welded in
From the florida swamp?
If need be
same
I only go in on non addictive drugs
herb
or psychedelics
zero physical withdrawal effects for me
Coke looks too good and costs too much to get hooked on
Thats the french.
viral load measuring only
does not show patient symptoms improved (that's specifically what your statement made me surprised at). They do not say that.
Beyond that, there are huge statistical problems with their non-randomized trial. But even ignoring that, they don't claim improvement in symptoms.
Thats the other french by the same group.
no patient centered end point showing improvement.
Despite the claim:
In this report we describe our results in patients treated with hydroxychloroquine in combination with azithromycin over a period of at least three days, with three main endpoints: i) clinical outcome ii) contagiousness as assessed by PCR and culture and iii) long of stay in infectious disease (ID) unit.
They actually don't have a clinical outcome studied. They are just describing their hospital and their criteria for discharge. They don't say, "here's some people treated and some not treated and the treated ones went home faster or got better faster". They actually just give the cocktail to everyone (93%).
This is an analysis of the french studies (primarily) using statistics. French study is a weak study by medical standards, even just in the since of bad stats.
The result?
To address this gap, more modern analytical methods including survival models, have been applied to these data, and show modest to no impact of HCQ treatment, with more significant effects from the HCQ-AZ combination, potentially suggesting a role for co-infections in COVID-19 pathogenesis. The trial of Gautret and colleagues, with consideration of the effect sizes, and p-values from multiple models, does not provide sufficient evidence to support wide-scale rollout of HCQ monotherapy for the treatment of COVID-19; larger randomzied studies should be considered. However, these data do suggest further study of HCQ-AZ combination therapy should be prioritized as rapidly as possible.
Yea but what about an OJ sinus rinse?
I have too much access, I know people that always have it and always want somebody to join in
I would enjoy it too much and partake often
I will have to trust you on that
Plus as a youth I worked on a crew of guys that blew their lives due to white drugs so I decided to not dabble
mushrooms every few year is what I really like
Thanks for the pro tip.
M
